Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.32 |
| ▸ | MET | P08581 | 1/20 | 0.31 |
| ▸ | AXL | P30530 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | PIM1 | P11309 | 1/20 | 0.30 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2984670 | 1.00 | GFER (0.33) | GFERPTGDR2METAXLLMNA | |
| SCHEMBL2996065 | 0.91 | KDM4E (0.33) | PTGDR2METAXLLMNAALDH1A1 | |
| SCHEMBL5822522 | 0.89 | GFER (0.38) | GFERPTGDR2METAXLLMNA | |
| SCHEMBL1749069 | 0.89 | GFER (0.38) | GFERPTGDR2METAXLLMNA | |
| SCHEMBL2990286 | 0.86 | PTGDR2 (0.39) | PTGDR2METAXLLMNAPIM1 | |
| SCHEMBL3000511 | 0.86 | LMNA (0.37) | PTGDR2METAXLLMNAALDH1A1 | |
| SCHEMBL2995941 | 0.85 | PTGDR2 (0.36) | PTGDR2METAXLLMNAALDH1A1 | |
| SCHEMBL2991313 | 0.84 | PCSK9 (0.34) | PTGDR2METAXLLMNAALDH1A1 | |
| SCHEMBL2989018 | 0.84 | PCSK9 (0.34) | PTGDR2METAXLLMNAMAPT | |
| SCHEMBL15085748 | 0.82 | PCSK9 (0.34) | PTGDR2LMNAALDH1A1MEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256141-A1 | NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2010-10-07 | — | — | US | disclosed |
| US-7786114-B2 | Bis-azaindole derivatives, preparation and pharmaceutical use thereof as kinase inhibitors | AVENTIS PHARMA S.A. (FR) | 2010-08-31 | — | — | US | disclosed |
| US-20080045561-A1 | Novel Bis-Azaindole Derivatives, Preparation And Pharmaceutical Use Thereof As Kinase Inhibitors | AVENTIS PHARMA S.A. (FR) | 2008-02-21 | — | — | US | disclosed |
| EP-1799691-A1 | NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS | Aventis Pharma S.A. (FR) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006037875-A1 | NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2006-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045561-A1 | Novel Bis-Azaindole Derivatives, Preparation And Pharmaceutical Use Thereof As Kinase Inhibitors | BRSK2, KSR2, CDK2 | GFER 4104/4885PTGDR2 1281/4885MET 1028/4885 |
| US-20100256141-A1 | NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS | BRSK2, KSR2, CDK2 | GFER 4104/4885PTGDR2 1281/4885MET 1028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.